ISSN:
1432-0584
Keywords:
Teniposide
;
VM-26
;
Chronic lymphocytic leukemia
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00320143
Permalink